Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
Rhea-AI Summary
Telix (TLX) will host an educational webinar on neurologic oncology, focusing on glioma, glioblastoma and theranostic approaches. Group Chief Medical Officer Dr David N. Cade will give a clinical update, followed by a fireside chat with leading European neuro-oncology and nuclear medicine specialists.
The webinar includes a Q&A with Dr Cade and Telix Therapeutics CEO Richard Valeix. It is scheduled for June 29, 2026, 5:00 p.m. EDT / June 30, 2026, 7:00 a.m. AEST, with online registration required.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – TLX
On the day this news was published, TLX gained 2.10%, reflecting a moderate positive market reaction. This price movement added approximately $70M to the company's valuation, bringing the market cap to $3.42B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Strategic collaboration | Positive | -2.8% | Theranostics collaboration with United Imaging focused on TLX101-Px in the U.S. |
| Jun 01 | Phase 3 data update | Positive | -2.8% | Part 1 Phase 3 ProstACT data for TLX591-Tx presented at ASCO 2026. |
| May 27 | Conference participation | Positive | +1.8% | Presentations at William Blair and Jefferies healthcare investor conferences. |
| May 18 | Phase 1 enrollment | Positive | -1.3% | Completion of IPAX-2 enrollment and dosing confirmation in first-line glioblastoma. |
| May 15 | Collaboration letters | Positive | -2.8% | LOIs to explore PSMA-PET imaging with EDAP and Profound Medical in prostate cancer. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
TLX has often traded lower after generally positive clinical and collaboration news over the past month.
Regulatory & Risk Context
Reported short interest appears relatively low, suggesting limited short-squeeze potential and a lower likelihood of extreme volatility driven purely by short covering.
Key Terms
neuro-oncology medical
glioma medical
glioblastoma medical
theranostics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these.
David N. Cade, MD, Telix Group Chief Medical Officer will provide a clinical update, which will be followed by a fireside chat with Nelleke Tolboom, MD, Nuclear Medicine physician and academic faculty member at UMC Utrecht (Netherlands) and Josef Pichler, MD, Head of the Neuro-oncological Center at Kepler University Hospital Linz (Austria).
The presentation will be followed by Q&A with Dr. Cade and Richard Valeix, CEO, Telix Therapeutics.
Webinar date and time:
EDT: Monday June 29, 2026, 5:00 p.m.
AEST: Tuesday June 30, 2026, 7:00 a.m.
Participants can register for the webinar at the following link:
https://s1.c-conf.com/diamondpass/10054826-mur5i9.html
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com